Meeting
2022 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).
Authors
Nick Pavlakis
Royal North Shore Hospital, St. Leonards, Australia
Nick Pavlakis , Kohei Shitara , Katrin Marie Sjoquist , Andrew James Martin , Anthony Jaworski , Sonia Yip , Do-Youn Oh , Markus H. Moehler , Tanios S. Bekaii-Saab , John Simes , David Goldstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04879368
DOI
10.1200/JCO.2022.40.4_suppl.TPS366
Abstract #
TPS366
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
First Author: Katrin Marie Sjoquist
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2013 ASCO Annual Meeting
INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).
First Author: Nick Pavlakis
Poster
2021 Gastrointestinal Cancers Symposium
Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.
First Author: Keisho Chin